Latest Oncology News

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Ashley Chan

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Learning to Dance

February 20th 2025

Jill Gilbert, MD

Networking is an underutilized skill that requires practice but can have a high impact on shaping your career path.

UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer

February 20th 2025

MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a collaboration dedicated to pediatric cancer care.

Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma

February 20th 2025

Jax DiEugenio

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Chris Ryan

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Latest Oncology Videos

Expert Insights on Recent Advancements in LS-SCLC

Reflections and Future Directions in R/R ALL

Dr Hernandez-Ilizaliturri on the Implications of Immunologic Changes With Venetoclax in CLL

Key Updates in the Treatment of ES-SCLC

Ongoing Research to Watch in Ovarian Cancer

Outpatient CAR T Therapy and Expanding Access

FLAURA and FLAURA2: Key Efficacy and Safety Data

Health Care Resource Utilization and Transition of Care

The Importance of Early Biomarker Testing in Managing Advanced BTC

Guiding Patients Through Advanced BTC Prognosis and Expectations

Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

Dr Vachhani on the Rationale for Evaluating Navtemadlin as a Ruxolitinib Add-On in Myelofibrosis

Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

Dr Pietrantonio on Amivantamab With/Without Chemotherapy in Right-Sided RAS/BRAF Wild-Type mCRC

Logistical Considerations for Delivering TCR Therapy to Patients

Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma

Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

Exploring Data of PI3K/AKT/mTOR Inhibitors in HER2– mBC

The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma

Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024

All Oncology News

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

Chris Ryan

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

FDA Grants Breakthrough Therapy Designation to Petosemtamab Plus Pembrolizumab for PD-L1+ HNSCC

February 20th 2025

Chris Ryan

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Critical Next Step in Thymoma/Thymic Carcinoma Field Involves Examining Immunotherapies

February 20th 2025

Megan Hollasch

Rohan Maniar, MD, details considerations when treating patients with rare thymic epithelial tumors as well as notable ongoing research in the field.

Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm

February 19th 2025

Ashley Chan

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

How Complementary Roles in Clinic and Industry Illuminate Avenues for Patient-Centered Cancer Care: With D. Ross Camidge, MD, PhD; and Geoff Oxnard, MD

February 19th 2025

D. Ross Camidge, MD, PhD

Drs. Camidge and Oxnard discuss novel EGFR inhibitors, the role of precision medicine in early cancer detection, and balancing clinical and industry roles.

Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium

February 19th 2025

Courtney Flaherty

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management

February 19th 2025

Ashling Wahner

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma

February 19th 2025

Ashling Wahner

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC

February 19th 2025

Jax DiEugenio

The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.

Roswell Park Blood Cancer Expert Honored With Prestigious GVHD Research Award

February 19th 2025

Roswell Park Comprehensive Cancer Center

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

Neoadjuvant Nivolumab Plus Chemo Improves OS in Resectable NSCLC

February 19th 2025

Chris Ryan

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.

Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC

February 19th 2025

Megan Hollasch

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

Detalimogene Voraplasmid Produces Complete Responses in BCG-Unresponsive NMIBC With CIS

February 19th 2025

Chris Ryan

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases

February 19th 2025

Ashley Chan

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Mirdametinib Provides Long-Awaited Treatment Option in NF1-Associated PN

February 18th 2025

Jax DiEugenio

Christopher L. Moertel, MD, discusses the FDA approval of mirdametinib for patients with neurofibromatosis type 1–associated plexiform neurofibromas.

See All News